Dedicated pipeline and competitive intelligence tracker for cell and gene therapy assets — clinical activity, manufacturing developments, regulatory milestones, and market-entry signals.
Strategic Intelligence Platform
-
CAR-T, TCR-T & viral-vector pipeline surveillance
​
-
Manufacturing & CDMO partnership intelligence
​
-
Regulatory milestone tracking across major markets
Trial Site & Investigator Intelligence
Pinpoint where every competing trial is running and who is running it, so feasibility and site selection start from current, registry-verified data instead of stale lists.
-
Site and investigator mapping (PI, study chair, sub-investigators) across ClinicalTrials.gov and country-specific registries
​
-
Site and investigator availability modeled from start, primary completion, and completion dates
​
-
Every location tied to indication, phase, and sponsor for feasibility and competitive site benchmarking
Model the label an asset could realistically earn before pivotal design is locked, with aspirational, base, and minimal-competitive scenarios built from regulatory precedent, society guidance, and competitor filings.
Label Forecast Intelligence
-
Aspirational, base, and minimal-competitive label scenarios for any asset entering pivotal development
​
-
Evidence base spanning regulatory guidance, society recommendations (NCCN, ASCO, ESMO, ACR, EULAR), and competitor and precedent protocols
​
-
Gap analysis of label requested versus granted across close competitors and prior approvals
Built for oncology
01
No generalist tooling — every platform is purpose-built for this therapeutic area.
Specialist-curated
02
Automation plus oncology experts who interpret what the data means.
Always current
03
Continuous updates so your intelligence is never out of date